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Background: The “Multidisciplinary Approach to the Study of Chronic Pelvic Pain” (MAPP) Research Network was
established by the NIDDK to better understand the pathophysiology of urologic chronic pelvic pain syndromes
(UCPPS), to inform future clinical trials and improve clinical care. The evolution, organization, and scientific scope of
the MAPP Research Network, and the unique approach of the network’s central study and common data elements
are described.
Methods: The primary scientific protocol for the Trans-MAPP Epidemiology/Phenotyping (EP) Study comprises a
multi-site, longitudinal observational study, including bi-weekly internet-based symptom assessments, following a
comprehensive in-clinic deep-phenotyping array of urological symptoms, non-urological symptoms and psychosocial
factors to evaluate men and women with UCPPS. Healthy controls, matched on sex and age, as well as “positive”
controls meeting the non-urologic associated syndromes (NUAS) criteria for one or more of the target conditions
of Fibromyalgia (FM), Chronic Fatigue Syndrome (CFS) or Irritable Bowel Syndrome (IBS), were also evaluated.
Additional, complementary studies addressing diverse hypotheses are integrated into the Trans-MAPP EP Study
to provide a systemic characterization of study participants, including biomarker discovery studies of infectious
agents, quantitative sensory testing, and structural and resting state neuroimaging and functional neurobiology
studies. A highly novel effort to develop and assess clinically relevant animal models of UCPPS was also undertaken
to allow improved translation between clinical and mechanistic studies. Recruitment into the central study occurred at
six Discovery Sites in the United States, resulting in a total of 1,039 enrolled participants, exceeding the original targets.
The biospecimen collection rate at baseline visits reached nearly 100%, and 279 participants underwent common
neuroimaging through a standardized protocol. An extended follow-up study for 161 of the UCPPS participants is
ongoing.
Discussion: The MAPP Research Network represents a novel, comprehensive approach to the study of UCPPS, as
well as other concomitant NUAS. Findings are expected to provide significant advances in understanding UCPPS
pathophysiology that will ultimately inform future clinical trials and lead to improvements in patient care.
Furthermore, the structure and methodologies developed by the MAPP Network provide the foundation upon
which future studies of other urologic or non-urologic disorders can be based.
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Trial registration: ClinicalTrials.gov identifier: NCT01098279 “Chronic Pelvic Pain Study of Individuals with
Diagnoses or Symptoms of Interstitial Cystitis and/or Chronic Prostatitis (MAPP-EP)”. http://clinicaltrials.gov/show/
NCT01098279
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Interstitial cystitis/bladder pain syndrome (IC/BPS) and
chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS) are defined by the hallmark symptom of chronic
pain in the region of the pelvis, urogenital floor, or exter-
nal genitalia, often accompanied by urinary symptoms,
such as urinary urgency or frequency [1,2]. The bladder
has historically been thought to be the origin of IC/BPS
symptoms; whereas the prostate gland has traditionally
been believed to be the source of CP/CPPS symptoms.
However, this viewpoint has come under recent chal-
lenge, in large part from the observation that many IC/
BPS and CP/CPPS patients exhibiting symptoms do not
have identifiable pathology in these organs [3-5].
The impact and burden of IC/BPS and CP/CPPS are
substantial. Patients suffer considerable morbidity result-
ing in a significant decrease in quality of life for both the
patient and his/her partner due to the physical and psy-
chological impact of the condition. In fact, the quality of
life of IC patients has been characterized as being worse
than that of patients undergoing dialysis [6]. In the U.S.,
the prevalence of IC/BPS symptoms has been estimated
to be 2.7% in women [7]; whereas the prevalence for
analogous symptoms is estimated to be 1.3% in men [8].
Prevalence estimates for CP/CPPS in men vary between
1.8 − 6.4%, depending upon case definitions and screen-
ing methods [9,10].
Traditionally, the diagnosis of IC required cystoscopy
and pathological findings, although more typically IC/
BPS is defined from patient reported symptoms, due to
the lack of consistent pathological findings, defined dis-
ease phenotypes or biological markers. Similarly, patientTable 1 Terminology used in the MAPP Research Network to
Term MAPP Network Research Defi
Urologic chronic pelvic pain syndrome
(UCPPS)
General term to describe idiopa
Network studies, this includes m
Interstitial cystitis/bladder pain syndrome
(IC/BPS)
Chronic unpleasant sensation (p
associated with lower urinary tra
Chronic prostatitis/chronic pelvic pain
syndrome (CP/CPPS)
Chronic idiopathic pelvic pain o
penis, or testicles, which is often
Non-Urologic Associated Syndromes
(NUAS)
General term used to describe s
rate greater than observed in th
focused on studying specific NU
though other examples exist (e.g
headaches, among others).symptoms are used to define CP/CPPS. Each of these
separate syndromes, however, may in fact represent a
group of related conditions that manifest in a similar
manner, but have differing etiologies. Based primarily on
their somewhat similar symptom profiles [2], IC/BPS
and CP/CPPS are here collectively termed urologic
chronic pelvic pain syndromes (UCPPS) (see Table 1 for
research definitions used in the MAPP Research Net-
work). As noted in the only published phenotyping sys-
tem, referred to as UPOINT [11,12], UCPPS patients
have significant symptoms across the urinary, psycho-
social, organ specific, infection, neurological/systemic
and tenderness domains, confirming the heterogenous
nature of these syndromes.
Despite intensive study over the past decade, clinical
trials have failed to identify effective therapies, and basic
science studies have failed to identify specific patho-
physiology for these conditions (for a review of previous
research efforts see companion Commentary by Clemens,
et al) [13]. Intriguing new clues into the pathophysi-
ology of UCPPS have come from several epidemiological
studies revealing shared pathophysiology between UCPPS
and other conditions having chronic pain as a cardinal or
prominent symptom (e.g., fibromyalgia, irritable bowel
syndrome, endometriosis, chronic fatigue syndrome, and
vulvodynia) [14-20]. Some of these chronic pain condi-
tions were previously thought to be due to “peripheral”
etiologies (i.e., damage or inflammation in the region of
the body where the individual was experiencing pain) but
are now known to have prominent central nervous system
(CNS) contributions (i.e. centralized pain). In light of this
new understanding, even the names of some of thesedescribed disorders under study
nition
thic chronic pelvic pain of urologic origin in men or women. In MAPP
en and women with IC/BPS, or men with CP/CPPS (see below).
ain, pressure, discomfort) perceived to be related to the urinary bladder,
ct symptoms, in the absence of infection or other identifiable causes.
r discomfort in males, commonly in the perineum, suprapubic region,
exacerbated by ejaculation or urination.
ymptom-based non-urologic syndromes which co-occur with UCPPS at a
e general population. Within the MAPP Network, initial efforts have
AS (fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome),
. vulvodynia, temperomandibular joint disorder, and migraine
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inflammation is not the primary cause of symptoms
(e.g., fibrositis became fibromyalgia, spastic colitis be-
came irritable bowel syndrome). In a similar manner, it
has been suggested that IC be renamed Bladder Pain
Syndrome (BPS), based on the fact that the majority of
patients do not have identifiable inflammation or even
pathology in the bladder [21]. Collectively, these find-
ings suggest the merits of exploring common under-
lying CNS pathophysiology (i.e., pain centralization or
augmentation) [22-24] rather than continuing the search
for a uniform malfunction of a single end organ [23].
In recognition of these emerging insights and the limi-
tations of previous basic research and clinical studies,
the NIDDK established the “Multidisciplinary Approach
to the Study of Chronic Pelvic Pain” (MAPP) Research
Network to better understand the etiology and treated
natural history of UCPPS. This network holds the prom-
ise of advancing UCPPS treatment through the identifi-
cation of clinically relevant patient subgroups potentially
requiring distinct interventions [13]. By moving beyond
traditional bladder- and prostate-focused investigations
toward an innovative multidisciplinary research strategy,
the MAPP Research Network is able to more fully inves-
tigate the relationship between UCPPS and non-urologic
associated syndromes (NUAS), and better define uro-
logic and more systemic contributions to the patho-
physiology of these disabling syndromes.
This manuscript describes the approach to clinical
phenotyping developed in the MAPP Research Network,
with a focus on its central epidemiological study. This
integrated research design is highly unique in its evalu-
ation of visceral pain and lower urinary tract symptoms
associated with UCPPS, and represents the largest and
most detailed characterization of UCPPS to date.
Methods/design
Scientific focus
The MAPP Research Network conducts complementary
basic, translational, and clinical science studies to inves-
tigate questions of clinical relevance, motivated by the
view that UCPPS involves substantial central systemic
mechanisms. Studies have been designed to advance
our understanding of the underlying pathophysiology
and etiology, treated natural history, “flare” etiology,
risk factors associated with biologic, genetic, and be-
havioral factors, and the discovery of comprehensive
characterizations of patient phenotypes. Another key
objective has been to address the relationships between
UCPPS and commonly associated non-urologic syn-
dromes (Table 1). The MAPP Network also supports
translational studies using UCPPS animal models founded
on key clinical criteria and leading hypotheses of UCPPS
etiology.MAPP network organization
The MAPP Research Network consists of six discovery
sites (Los Angeles, CA; Chicago, IL; St. Louis, MO; Iowa
City, IA, Seattle, WA, and Ann Arbor, MI); several satel-
lite sites (Miami, FL; Birmingham, AL; Palo Alto, CA;
Boston, MA; Kingston, Ontario, Canada (CA); a data
coordinating core (DCC) in Philadelphia, PA; a tissue
analysis and technology core (TATC) in Aurora, CO; a
neuro-imaging scan repository and reading center (Los
Angeles, CA); an external experts panel (EEP); and
NIDDK project scientists (Figure 1).
MAPP network core functions
The DCC provides biostatistical design and analysis leader-
ship for all studies, serves as the central site for electronic
protocol and data management system development, web-
based deployment of data capture tools, data acquisition
and storage, and promotes network-wide quality assurance
across all protocol-specific domains of data. The DCC also
provides administrative and project coordination support,
including development and maintenance of a public web-
site (http://www.mappnetwork.org/). The TATC provides a
central location for bio-specimen processing, storage, and
analysis of blood, urine, and DNA samples. The TATC
established and implemented standards for specimen
collection, identification, and handling to promote con-
sistent specimen collection procedures. DCC and TATC
personnel conducted centralized coordinator training
before initiating patient enrollment, with follow-up re-
fresher training at periodic Steering Committee meet-
ings. Standardized modular barcoded collection kits
with specimen annotation forms for blood, urine, and
cheek swab DNA were designed for use at all recruit-
ment sites. The data-sharing model allows sites to enter
material requests, specimen collection and shipment
information through the DCC portal, with replication
in real-time between both DCC and TATC databases
(Figure 2). Sites request kits via the DCC portal, follow-
ing which the TATC sends a shipment of unlinked spe-
cimen kits, uniquely identified with a barcode system,
to the site, which are individually linked through the
DCC portal to a MAPP participant at the time of bios-
pecimen collection. Blood specimens are shipped on
the day of collection to the TATC for next day delivery;
whereas cheek swab and urine specimens are tempor-
ary stored at the collection sites and batch-shipped to
the TATC. At-home specimen collection is facilitated
by participants, using barcoded collection materials
and pre-labeled shipping containers for direct shipping
to the TATC. Centralized processing at the TATC en-
sures standardized processing using best practice stan-
dards [25]. Derivative specimen aliquots are barcoded
without participant identifying information, allowing for
blinded discovery and validation projects. A rigorous
Figure 1 MAPP Research Network Discovery and Collaborating Sites, Data Coordinating Core (DCC) and the Tissue Analysis and
Technology Core (TATC).
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mented between the DCC and TATC to ensure unambigu-
ous links between specimen and participant data. Discovery
sites submit specimen requests for research projects to the
DCC. Sharing of real-time specimen inventory and annota-
tion data between the TATC and DCC database allows fullFigure 2 Data and Materials Flow Schematic: Left Panel (Data Coordin
Technology Core (TATC) Database).control by the DCC to match specimens with the required
clinical data, and select specimens at the aliquot tube level.
After selection by the DCC, a specimen distribution re-
quest is transferred to the TATC, triggering shipment to
the discovery site. Real-time updates allow the DCC to
monitor progress of distribution projects.ating Core (DCC) Database) and Right Panel (Tissue Analysis and
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QST is a specialized form of assessment that utilizes
Pressure Pain Threshold (PPT) to assess pain sensitivity
to standardized evoked stimuli. The PPT was deter-
mined by using blunt pressure delivered by a 1-cm2
hard-rubber probe to the thumbnail bed of the partici-
pant’s non-dominant hand [26-28]. The thumbnail is
considered a “neutral site”, both because it is distant
from the pain that these individuals are experiencing,
and this site has been repeatedly shown to be a good
measure of overall “central” pain threshold [29]. Evoked
pressure pain, rather than heat pain threshold testing
was chosen for MAPP studies for several reasons; first,
QST studies have found that pressure pain testing differ-
entiates IC from healthy controls better than does heat
stimulation [16,30,31], and secondly, pressure testing
was more easily deployed in a standardized manner
across multiple sites.
Neuroimaging and functional neurobiology
Neuroimaging and functional neurobiology studies sup-
port overall participant characterization, as well as spe-
cific trans-MAPP brain imaging studies. These studies
were designed to identify differences in brain structure
and connectivity [32,33] as well as differences in regional
intrinsic oscillation frequencies and resting state con-
nectivity of the brain [34] between UCPPS patients and
control groups. A standardized protocol was developedTable 2 Number of participants (target, enrolled) by cohort, s
participants with biospecimens by type, MRI scans completed
Cohorts No. of participants
by cohort
No. of participants with b
Target
size
Actual
enrolled
Cheek
swab
Biomarker
samples
In
Plasma Urine VB
UCPPS (Duration of symptoms)
Male < 2 Yrs 95 90 90 90 90 90
Male ≥ Yrs 95 101 100 100 101 10
Female < 2 Yrs 95 89 89 86 89 89
Female ≥2 Yrs 95 144 144 142 144 14
Total 380 424 423 418 424 42
Healthy controls
Male 190 182 182 177 181 17
Female 190 233 233 228 232 23
Total 380 415 415 405 413 40
Positive controls
Male 95 44 44 43 43 43
Female 95 156 156 154 154 15
Total 190 200 200 197 197 19
Overall total 950 1,039 1,038 1,020 1,034 1,0to acquire structural (grey matter), diffusion tensor im-
aging; white matter (integrity and connectivity) and rest-
ing state images of the brain, as well as functional
neurobiology studies across study sites. The magnetic
resonance imaging/functional magnetic resonance im-
aging (MRI/fMRI) data repository for this study was
established at the UCLA Center for Neurobiology of
Stress (http://pain.med.ucla.edu/), in close collaboration
with UCLA-Laboratory of Neuroimaging (LONI), which
has extensive experience in the collection, storage and ana-
lysis of large multi-site MRI data sets (loni.usc.edu) [35].
Biomarker and infectious etiology studies
As a component of the Trans-MAPP EP Study protocol,
biological samples (urine, plasma, and cheek swab DNA)
were collected at Discovery Sites at baseline (UCPPS
patients and control cohorts) and the 6- and 12-month
in-clinic office visits (UCPPS patients) (see Table 2 for
details on samples collected). In addition, a specialized
single-use at-home collection kit was developed for use
by UCPPS patients at the time of self-reported flare.
These samples were archived at the TATC and distrib-
uted to MAPP Network investigators, in conjunction
with associated clinical data managed at the DCC, to
support integrated studies to identify and characterize
UCPPS biological markers (biomarkers) and to examine
the potential contributions of infectious agents to
UCPPS. The biomarker study uses UCPPS and controlex (UCPPS: duration of symptoms), and number of
and PPT data collected at baseline visit
iospecimens No. of participants
with MRI scans
No. of Participants with
Pain Pressure Threshold
(PPT) measures
fectious etiology
urine samples
At baseline During
follow-up
1 VB2 VB3
90 39 13 19 20
0 100 42 22 12 20
88 0 22 20 19
2 139 0 41 11 23
1 417 81 98 62 82
6 174 64 38 40 0
2 227 0 79 60 0
8 401 64 117 100 0
43 10 17 8 0
4 152 0 47 27 0
7 195 10 64 35 0
26 1,013 155 279 197 82
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utility of previously identified, candidate markers and to
identify new markers in a discovery-based approach using
proteomics platforms. The infectious etiology study exam-
ines VB1 and VB2 (males and females) and VB3 (males)
urine samples (Table 2) through advanced 16S deep se-
quencing methods to assess UCPPS and control microbial
profiles and to address hypotheses regarding an infectious
basis for symptom development and fluctuations, includ-
ing symptom flare. Archived DNA samples will be used
for targeted epigenetics and genetic investigations.
Flare assessment in UCPPS
Currently it is unknown what triggers a flare of UCPPS
symptomatology. Putative risk factors for flares (e.g., diet-
ary factors, physical activity, stress, sexual activities, recent
infections) were assessed for participants reporting a flare
(limited to three assessments for subjects reporting >3
flares). The same potential flare risk factors were also col-
lected during randomly selected follow-up contacts for
participants when not reporting flares, serving as within-
person control data. A home collection kit was designed
to allow participants to collect urine samples for bio-
marker and infectious etiology studies at their first re-
ported “flare”. In addition, each participant collected a
reference urine sample using the home collection kit at
one of the three randomly selected non-flare time points
during the first four months. A full set of flare and non-
flare biomarker and infectious etiology urine specimens
was successfully collected from 188 (44%) of the partici-
pants. Another 44 (10%) participants provided only a flare
specimen set; whereas 123 (29%) of participants provided
only a non-flare specimen set. This reference specimen,
together with the urine specimens collected during the in-
clinic visits will be analyzed, and compared with the flare
specimen, to investigate potential biomarkers and infec-
tious agents that are uniquely present in urine during
symptom flares.
Baseline self-report battery characterizing UCPPS
and controls
Extensive clinical phenotyping was conducted to characterize
UCPPS patients, positive controls and healthy controls at
baseline. A description of the self-report battery follows
categorized by: General Socio-Demographic and Medical
History; Urological Specific Measures; and Non-Urological
co-morbidities and diagnostics.
General socio-demographic and medical history
Data on age, sex, race/ethnicity, education, marital sta-
tus, and income were collected from participant self-
report. A directed medical history was gathered on each
participant that included co-morbid conditions, early life
infection history, concomitant medication use (i.e., name,dose, frequency and route of administration), previous
treatments for UCPPS, and family medical history (i.e., his-
tory of chronic pain and psychiatric disorders in parents,
grandparents, aunts, uncles, siblings, and children). A
physical examination included measurement of height,
weight and blood pressure as well as abdominal, pelvic,
and rectal examinations. Pelvic floor muscle tenderness
(yes/no) and suprapubic tenderness (yes/no) were evalu-
ated in each participant. In women, the presence and de-
gree of pelvic organ prolapse was recorded (above or
below the hymenal ring). In men, penile exam (circumcised
or not), prostate examination (enlarged, irregular, tender)
and scrotal examination (varicocele, hydrocele, mass, her-
nia) findings were recorded.
Urological specific measures
Urological measures were selected purposefully to pro-
vide continuity between MAPP and pre-existing litera-
tures on IC/BPS and IC/CPPS. The urological measures
thus sought to assess symptoms that have been historic-
ally considered relevant to UCPPS with instruments de-
signed specifically for this population (Table 3).
Symptom and health care utilization Questionnaire
(SYM-Q) A 12-item questionnaire was developed specif-
ically for this study. All participants completed this
questionnaire at baseline and at bi-weekly intervals
throughout the 48-week study period. The SYM-Q in-
quires about (1) pain, urgency, frequency, (2) the pres-
ence of non-urological pain symptoms, (3) mood, (4)
health care seeking, (5) last menstrual period, and (6)
the occurrence of symptom worsening (flares).
Interstitial Cystitis Symptom Index (ICSI) and problem
index (ICPI) (ICINDEX) This instrument consists of two
4-item questionnaires. The ICSI quantifies urinary and
pain symptoms in patients with IC/BPS, and the ICPI
assesses the degree of bother associated with these
symptoms [36].
American Urological Association Symptom Index
(AUASI) This validated 8-item questionnaire assesses the
severity of voiding symptoms (e.g., frequency, urgency,
nocturia, sense of incomplete emptying, intermittency,
slow stream, straining to void) and associated bother in ei-
ther sex [37].
Brief Flare Risk Factor Questionnaire (BFRFQ) Devel-
oped specifically for use in the MAPP Research Network
as a means of better understanding flares in UCPPS, the
BFRFQ contains 33 items documenting potential causes
of flares. It includes questions about diet, physical activ-
ity, stress, sexual activity, and infection.
Table 3 Baseline phenotyping battery for MAPP:
urological self-report questionnaires
Instrument Subscales
Symptom and Health Care Utilization
Questionnaire (SYM-Q)
1. Pain, urgency, frequency
2. Urologic/Pelvic Pain severity
3. Non-urologic/Pelvic Pain
severity
4. Mood
5. Most bothersome symptom
6. Medical care seeking
7. Menstrual information
8. Flare status
Interstitial cystitis symptom and
problem index
1. IC Symptom Index (ICSI)
2. IC Problem Index (ICPI)
American Urological Association
Symptom Index Score
1. AUASI total score
Rice case definition questionnaire 1. RICE total score
Brief flare risk factor questionnaire 1. Flare timing, symptoms, and
symptom severity
2. Cause attribution
3. Foods
4. Drinks
5. Physical and sedentary
activities
6. Stress
7. Sexual activity
8. Infections
Genitourinary Pain Scale (GUPI) 1. Pain
Male version 2. Urinary symptoms
Female version 3. Quality of life
4. Total
Female sexual function index 1. FSFI total score
International index of erectile
function
1. IIEF total score
University of Washington male sexual
function scale
1. Pain with ejaculation
2. Premature ejaculation
3. Difficulty reaching ejaculation
Self-esteem and relationship
questionnaire
1. SEAR total score
Males
Females
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definition The 5-item RICE case definition question-
naire was designed for epidemiological studies to iden-
tify the presence of IC/BPS symptoms in men and
women [9]. We used it to identify sub-groups with or
without bladder pain and urgency due to pain, pressure,
or discomfort.Genitourinary Pain Index (GUPI) This 9-item instru-
ment was developed by modifying the original NIH-
Chronic Prostatitis Symptom Index (CPSI) [38]. Several
new items about bladder-specific pain were added, and
male gender-specific items were replaced with female-
gender specific items for women. The GUPI is applicable
to men and women to assess pain symptoms, urinary
symptoms, and quality of life as separate sub-scales, and
overall as a total score [39].
Female Sexual Function Index (FSFI) This 19-item
scale provides an overall assessment of female sexual
functioning over the past 4 weeks, and includes domain
scores in six areas: sexual desire, arousal, lubrication, or-
gasm, satisfaction, and pain, as well as a total score for
sexual dysfunction [40].
International Index of Erectile Function (IIEF) The
IIEF is a multidimensional instrument consisting of 15
items and 5 domains of male sexual function: erectile
function, orgasmic function, sexual desire, intercourse
satisfaction, and overall satisfaction. Total scores indicate
greater levels of sexual dysfunction [41].
Washington Male sexual function scale (MSFS) This
instrument was used in males to rate the severity of the
following symptoms: pain with ejaculation, lack of inter-
est in sexual activity, premature ejaculation, and diffi-
culty reaching ejaculation [42].
Self-Esteem And Relationship questionnaire (SEAR:
M & F) The SEAR is a 14-item measure validated to as-
sess psychosocial impact of erectile dysfunction. The
measure assesses an overall score, sexual relationship
satisfaction, confidence, and self-esteem. The measure
was adapted for use in women by omitting the two
male-specific items [43].
Non-urologic co-occurring symptoms and diagnostics
Although pain is experienced locally at a site of discom-
fort, it is often accompanied by other symptoms that in-
fluence pain processing, modulation, and ultimately how
it is experienced. Understanding these other influential
factors can provide insight into the mechanisms associ-
ated with the etiology and maintenance of chronic pain.
Thus, the following symptoms and traits were assessed
in each participant (Table 4).
History of co-occurring somatic symptoms The Com-
plex Multi-Symptom Inventory (CMSI) [44] is a 41-item
symptom checklist of past year illnesses specific to func-
tional syndromes (e.g., fibromyalgia (FM), chronic fa-
tigue syndrome (CFS), irritable bowel syndrome (IBS),
Table 4 Baseline phenotyping battery for MAPP:
non-urological self-report questionnaires
Instrument Subscales
Complex Multi-Symptom Inventory (CMSI)
(Diagnostics of co-morbid functional
disorders and overall symptom burden)
1. Fibromyalgia
2. Chronic fatigue syndrome
3. Irritable bowel syndrome
4. Vulvadynia
5. Migraine
6. Temporomandibular
disorders
7. Past year total symptom
burden
Brief Pain Inventory (BPI) (General
clinical pain)
1. Severity
2. Interference
3. Medications
4. Relief from medications
5. Body map: overall
6. Body map: male genital
7. Body map: female genital
Short Form-12 (Functional status) 1. Physical status
2. Physical role status
3. Bodily pain
4. General health
5. Energy/vitality
6. Social functioning
7. Mental health
8. Role limitations
(emotional)
9. Composite physical (PCS)
10. Composite mental
health (MCS)
PROMIS: Fatigue 1. Total score (t-score)
PROMIS: Sleep disturbance 1. Total score (t-score)
Multiple Abilities Self-Report Questionnaire
(MASQ) (Perceived cognitive problems)
1. Language ability
2. Visio-spatial ability
3. Verbal memory
4. Visual memory
5. Attention/concentration
Perceived Stress Scale (PSS) 1. Total score
Hospital Anxiety and Depression Scale 1. Depressive symptoms
(HADS:D)
2. Anxiety Symptoms
(HADS:A)
PROMIS: Anger 1. Total score (t-score)
Positive and Negative Affect Scale
(PANAS)
1. Positive affect
2. Negative affect
3. Affect balance
Table 4 Baseline phenotyping battery for MAPP:
non-urological self-report questionnaires (Continued)
International Personality Item Pool (IPIP) 1. Neuroticism
2. Extroversion
3. Agreeableness
4. Conscientiousness
5. Openness to experience
Coping Strategies Questionnaire
(Catastrophizing scale)
1. Cat score
Beliefs in Pain Control Questionnaire
(BPCQ)
1. Internal locus of control
2. Powerful doctors
(external locus)
3. Chance (external locus)
Childhood Traumatic Events Scale (CTES)
Recent Traumatic Events Scale (RTES)
1. Age of each trauma
2. Intensity of each trauma
3. Confiding in others for
each trauma
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disorders (TMD). The checklist provides a proxy for the
presence of these comorbid conditions; whereas the fol-
low–up assessment module uses the standardized diag-
nostic criteria for each condition [44]. The summed
checklist has been interpreted as representing the overall
symptom burden from somatic or functional conditions.
Clinical pain The Brief Pain Inventory (BPI) is a 15-item
self-report measure that has been validated for use in a
wide variety of pain states [45]. The BPI assesses for the
presence of pain, pain intensity (i.e., worse, least, average,
current), and functional interference from pain. It also
catalogues the types of medications being used; the per-
centage of pain relief obtained from medications, and as-
sesses pain distribution (via a body map). For purposes of
the MAPP Research Network, the body map of the BPI
was replaced with a more detailed body map used in epi-
demiological studies to better identify widespread pain by
body regions [46]. This more detailed body map was fur-
ther modified to include larger scale depictions of the pelvic
and genital regions. This body map was scored to identify
those where pelvic pain was confined to the pelvic region
(i.e., pelvic pain only) or was more widespread extending
beyond the pelvic region (i.e., pelvic pain and beyond).
Functional status The SF-12 [47], is a 12-item measure
of functional status and generic quality of life. The in-
strument assesses eight domains of health status: phys-
ical functioning, role limitations because of physical
problems, bodily pain, general health perceptions, en-
ergy/vitality, social functioning, role limitations due to
emotional problems, and mental health. It also provides
both a composite physical functioning score (PCS) and a
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these measures indicate better functioning within the
domain.
Fatigue and sleep disturbance The NIH Patient Re-
ported Outcomes Measurement Information System
(PROMIS) developed questionnaires for fatigue and
sleep disturbance that can be used across disease con-
ditions. Participants completed the following PROMIS
short-forms: Fatigue (7-items) and Sleep Disturbance
(8-items) [48]. Higher scores on these measures indicate
worse symptomatology.
Cognitive difficulties The Multiple Ability Self-Report
Questionnaire (MASQ) assessed the self-perception of
having cognitive difficulties [49]. This is a 38-item ques-
tionnaire comprised of 5 domains of cognitive concerns:
language ability, visio-spatial ability, verbal memory, visual
memory, and attention/concentration. Validation studies
have found the self-reported cognitive difficulties to corres-
pond to performance-based indices of the same constructs
[49]. Higher scores on each scale indicate more problem-
atic perceptions.
Stress Perceived stress was measured using the 10-item
Perceived Stress Scale (PSS) [50]. The PSS measures the
degree to which situations are perceived as being unpre-
dictable, uncontrollable and overwhelming. Higher scores
indicate more stress.
Emotional distress Emotional distress was assessed
across several affective domains. Depressive and anxiety-
related symptoms were assessed using the Hospital Anx-
iety and Depression Scale (HADS) [51]. The HADS is a
14-item self-report questionnaire developed for use in
non-psychiatric settings. This instrument provided both
a depressive symptom and anxiety symptom score with
validated cut-off scores associated with clinically relevant
levels of each affective domain. Anger was assessed with
the 8-item anger short form from PROMIS [48]. A poten-
tial source of resilience, (i.e., positive affect), was assessed
using the Positive and Negative Affect Schedule (PANAS)
[52]. This 20-item questionnaire provides both a positive
and negative affect score. On each mood measure, higher
scores indicate greater problems with mood.
Personality traits Personality was measured using the
International Personality Item Pool (IPIP) short form
[53]. The IPIP is a public-domain, 120-item instrument
that was developed to reflect assessment of five person-
ality domains: extraversion, neuroticism, agreeableness,
conscientiousness, and openness to experience. Higher
scores indicate greater strength of each personality trait.Catastrophizing Catastrophizing refers to the percep-
tion that pain is overwhelmingly awful and the worst im-
aginable burden that one can endure. This cognitive
perception was assessed using the 6-item Catastrophizing
sub-scale from the Coping Strategies Questionnaire (CSQ)
[54] a metric for measuring this construct. Higher scores
indicate greater catastrophizing.
Locus of control The Beliefs in Pain Control Question-
naire (BPCQ) [55] is a 13-item questionnaire designed
to evaluate beliefs regarding whether pain is under per-
sonal control or under the control of forces external to
the patient. Three scales can be derived: (1) Internal
scale – measuring beliefs that pain can be personally
controlled (2) Powerful Doctors – an external locus of
control scale measuring beliefs that pain control is in
the hands of powerful others, and (3) Chance Happen-
ings – a second external locus of control scale measuring
beliefs that pain is controlled by chance or misfortune.
Higher scores on each scale indicate greater strength of
each belief.
Early life trauma history The Childhood Traumatic
Events Scale (CTES) [56] is composed of two forms. The
first assesses childhood traumatic events that occurred
prior to the age of 17. Domains include death of a close
family member or friend, parental separation, physical
abuse including sexual assault, serious illness, and other.
For each question, the age of trauma, perceived intensity
of the trauma, and whether or not confiding in others
occurred is assessed. The second form is labeled Recent
Traumatic Events Scale (RTES). It assesses essentially
the same traumatic domains with the exception that the
timeframe is within the last 3 years, parental separation
is replaced with spouse or significant other separation,
and a new category of job change is added. This instru-
ment can be scored to identify the intensity of each type of
trauma or intensities can be summed across all traumas.
This form is unique in that it also assesses whether the per-
son confided in another individual about the trauma.
The trans-MAPP epidemiology/phenotyping study
The principal study conducted by the MAPP Research
Network is a prospective observational study of the
treated natural history of UCPPS − the Trans-MAPP
Epidemiology/Phenotyping (EP) Study (Figure 3). This
study serves as the central clinical phenotyping effort for
all MAPP Network participants, and the platform for add-
itional, integrated and complementary phenotyping efforts.
Trans-MAPP EP study participants
As illustrated in Figure 3, the Trans-MAPP EP Study
specifically targeted the recruitment of 380 UCPPS
Figure 3 Trans-MAPP Epidemiology and Phenotyping (EP) Study of UCPPS Patients, Control (Healthy, Positive) Groups, Biomarker and
Infectious Etiology Studies, Pressure Pain Threshold Study, Structural and Resting State Neuroimaging Study, and Functional
Neurobiology of UCPPS Study.
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up. An additional 380 healthy controls matched on sex
and age, and 190 “positive” controls, meeting the criteria
for one or more of the targeted NUAS were also recruited
and phenotyped at baseline. In addition to the self-
reported characterization of all study participants at
baseline, a standardized protocol for the collection of
biological samples (cheek swabs, plasma, urine) was
implemented for additional multi-site biomarker and
infectious etiology studies, quantitative sensory testing
was used to measure pressure pain threshold (PPT), flares
were assessed, and structural and resting state neuroimag-
ing and functional neurobiology studies were also con-
ducted to characterize UCPPS patients and controls.
The original recruitment targets were 50% males and
50% females, for both UCPPS and control cohorts. In
addition, 50% of both male and female UCPPS participants
were targeted to have recent onset of chronic pelvic pain
symptoms (operationalized as < two years) and 50% longer
symptom duration (operationalized as ≥ two years). Conse-
quently, the recruitment target sample size was 95 for each
of these four UCPPS participant subgroups (Table 2). The
healthy control group targets were 190 males and 190
females, aiming to balance age and race/ethnicity dis-
tributions within the UCPPS subjects. The targets for
positive controls were not specified, except for a total
of 95 males and 95 females with one or more NUAS.
UCPPS Inclusion criteria
Inclusion criteria for UCPPS participants were: 1) a diagno-
sis of IC/BPS or CP/CPPS, with urologic symptoms present
a majority of the time during any 3 of the past 6 months
(CP/CPPS) or the most recent 3 months (IC/BPS); 2) at
least 18 years old; 3) reporting a non-zero score forbladder/prostate and/or pelvic region pain, pressure or dis-
comfort during the past 2 weeks; and 4) consented to pro-
vide a blood or cheek swab sample to test DNA for genes
related to the main study goals.
UCPPS exclusion criteria
Exclusion criteria for UCPPS consisted of the following:
symptomatic urethral stricture, on-going neurological
conditions affecting the bladder or bowel, active auto-
immune or infectious disorders, history of cystitis caused
by tuberculosis or radiation or chemotherapies, history
of non-dermatologic cancer, current major psychiatric
disorders, or severe cardiac, pulmonary, renal, or hepatic
disease. In addition, males diagnosed with unilateral orch-
algia without pelvic symptoms, and males with a history of
microwave thermotherapy, trans-urethral or needle abla-
tion or other specified prostate procedures were excluded.
Eligibility criteria for controls
To ensure a clearly-defined healthy control subgroup, po-
tential control participants were excluded if they reported
any pain in the pelvic or bladder region or chronic pain in
more than one non-urologic body region. Like healthy
controls, positive controls needed to be free of pain in the
pelvic region, but also needed to qualify on the CMSI as
having one of the targeted co-morbid conditions.
Screening and baseline procedures
The screening and enrollment process utilized one in-
clinic baseline study visit for informed consent and eligibil-
ity confirmation. This baseline visit was structured so that
essential information, such as brief symptoms analogous to
those used in previous UCPPS clinical studies (e.g., pain,
pressure, discomfort and sex-specific symptom criteria)
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to the conduct of more intensive, invasive and time-
consuming procedures (Figure 4). Persons meeting initial
eligibility were then invited to complete the Trans-MAPP
EP Study assessments, and were enrolled only after a nega-
tive 48-hour urine culture report. Eligible participants then
underwent extensive baseline characterization using the
standardized battery of urologic and non-urologic assess-
ment instruments described previously. Biosamples, QST,
and neuroimaging was also collected concurrently with the
self-report information at baseline. Healthy controls, as
well as “positive” controls (i.e., individuals with one or
more non-urologic associated syndromes of primary inter-
est; Table 2), were also enrolled but only underwent a sin-
gle phenotyping assessment and biosample collection at
baseline identical to that of participants with UCPPS.
Longitudinal phenotyping schedule
After the extensive baseline assessment, participants were
administered a small subset of the assessment battery forFigure 4 Sequence of Trans-MAPP Epidemiology and Phenotyping (E
Enrollment into the EP Study.48 weeks via internet-based bi-weekly / bi-monthly assess-
ment questionnaires. More extensive assessment was pos-
sible at the in-clinic visit occurring at 24 and 48 weeks.
Biological samples (e.g., DNA, serum, and urine) were col-
lected in-clinic at baseline and at 24 and 48 weeks, as well
as through home collection kits when patients reported
symptom worsening (“flares”). The sequence of data and
biospecimen collection is illustrated for the Trans-MAPP
EP Study in Figure 4.
Recruitment and retention of participants
Participant recruitment was conducted through the ur-
ology/urogynecology clinics at each of the clinical sites
from 12/14/2009 through 12/14/2012. As summarized
in Table 2, the MAPP Research Network enrolled 1,039
men and women, including persons with UCPPS (n =
424); “positive controls” with other NUAS (n = 200 for
all conditions); and healthy controls (n = 415), exceeding
specified target sizes. Given the success of recruitment
and value of this phenotypic data, individuals withP) Study Screening, Phenotyping, Biospecimen Collection and
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in this manner in the subsequent phases of the network.
During the follow-up period, retention was promoted
by the research coordinators by sending reminder mes-
sages to participants to provide their bi-weekly symptom
assessments. Participants who missed these assessments
were contacted by phone for further prompting to facili-
tate ongoing participation. The MAPP Research Net-
work continued follow-up visits through 12/14/2013.
The participant retention rate for the final clinic visit at
48 weeks was 83% (349/420), with remarkable adherence
(83% missing no more than 3 monthly contacts). Among
the 349 UCPPS participants completing the 48-week
assessment, 161 (46%) to date have agreed (with re-
consent) to participate in an ongoing extended follow-
up study with internet-based symptom assessment
every 4 months.
Self-report and QST data
Currently, extensive baseline self-report phenotypic data
is available on 424 individuals with UCPPS, 200 positive
controls, and 415 healthy controls. Longitudinal assess-
ment from all UCPPS participants was initiated with bi-
weekly internet-based data capture, with 349 participants
completing the 48 week final clinic visit. QST studies
were performed on a subset of trans-MAPP EP partici-
pants from each site (n = 279) [59].
Biological specimen collection
The biospecimen capture rate at the baseline visit was
high, exceeding 98% for the cheek swabs, plasma and
urine biomarker samples, and the first-void and infec-
tious etiology mid-stream urine samples (VB1/VB2), as
shown in Table 2. Success can be attributed to the tight
integration of clinical procedures and biospecimen col-
lection, the design of standardized collection kits, and
the data sharing procedures (Figure 2) between the DCC
and the TATC. In addition, consistent communication
with research coordinators and monthly conference calls
developed a strong collaborative environment, promot-
ing timely response to data collection issues. The bio-
samples are examined in a set of integrated research
protocols within the MAPP Network.
Statistical considerations
All data are initially examined using exploratory descrip-
tive methods, investigating potential differences between
males and females, and between groups (i.e., UCPPS,
healthy and positive controls). Categorical variables,
including dichotomous factors, are summarized by pro-
portions and compared among groups using standard
chi-square tests of association and generalized Mantel-
Haenszel methods, as described in Landis et al. [60].Extensive baseline phenotype data are being investigated
within a multi-stage cluster analysis [61] to construct clin-
ically relevant subgroups, using a distance-dissimilarity
matrix and clustering subjects using the average linkage
method [62]. For each domain, the variables that are con-
tributing most to the differences among the domain-
specific clusters are identified.
Studies aimed at characterizing symptom pattern
change over time utilize standard methods for longitu-
dinal data analysis. For measured continuous outcomes,
the primary models used are random coefficient growth
curve models in which random effects due to subject and/
or time are included to account for the correlation among
repeated observations on each subject [63,64]. For binary
or ordinal outcomes, the methodology of generalized esti-
mating equations are being implemented to evaluate
changes over time via logistic models [65,66].
To adjust for regression-to-the-mean effects, data from
a pseudo-run-in period from baseline, 2 and 4 weeks of
follow-up are being used to construct a baseline measure
of variability, and a within-person slope is estimated be-
ginning at 4 weeks through the final visit at 48 weeks.
Studies aimed at evaluating factors related to the extent of
symptom variability over time are being conducted utiliz-
ing subject-specific estimates of mean squared error about
the estimated slope of longitudinal symptom outcomes.
Discussion
The MAPP Research Network overall research strategy,
and specifically its primary clinical protocol, the Trans-
MAPP EP Study, represents a novel investigative direction
for the field. Moreover, the integrated approach to sys-
temic phenotyping allows a wealth of clinically important
questions to be addressed. Through the use of state-of-
the-art research methods developed by network investiga-
tors, and adopted from the broader pain field, the MAPP
Network seeks to determine if UCPPS patients exhibit
similar findings as have been observed for patients with
non-urologic chronic pain. The recruitment of a healthy
control group (individuals without urologic pain symp-
toms) and a “positive” control group (those with chronic
non-urologic associated functional pain syndromes) allow
MAPP Network investigators to search for novel clin-
ical and biological measurements that may be unique
to UCPPS, or that define clinically distinct UCPPS sub-
groups. The bi-weekly longitudinal assessments provide
valuable information about UCPPS symptom variability
and flares and, indeed, this effort has forged new
ground in the highly effective acquisition of extensive,
longitudinal clinical data through internet-based plat-
forms developed specifically for this study. These ex-
tensive data collection efforts described here were
developed to address a series of overarching study hy-
potheses prioritized by the MAPP Network for their
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care for UCPPS patients:
1. Individuals with UCPPS, measured at baseline and
followed longitudinally for one year, as well as
asymptomatic and disease comparator controls
(e.g., CFS, FM, IBS) measured only at baseline, will
make it possible to identify biologically-derived
UCPPS subsets of individuals with UCPPS who:
(a) have differing underlying pathogenesis resulting in
their symptoms, and (b) would likely respond to
different treatments.
2. There are two subsets of UCPPS patients: those with
primarily pelvic symptoms, and those who also
display many non-urological symptoms and syndromes.
These latter individuals have a more systemic condition,
characterized by a different natural history than those
with isolated UCPPS symptoms, including a higher
likelihood of: (a) symptom progression or continuation,
(b) symptom variability, and (c) decreased quality of
life and increased healthcare seeking behavior than
those with primarily pelvic symptoms.
3. Individuals with UCPPS who have been
symptomatic for longer periods of time
(operationalized as 2+ years) will have more severe
overall symptoms, decreased quality of life, and
greater psychological co-morbidities than individuals
with more recent (<2 years) onset of symptoms.
4. IC/BPS in females and CP/CPPS in males represent
the same underlying condition. Using common
phenotyping protocols in males and females, the
high rate of non-urological symptoms and syndromes
(NUAS) noted previously in women with IC/BPS will
also be noted in men with CP/CPPS.
5. A variety of stressors (e.g, dietary, infectious,
psychological) will be shown in case-crossover
studies to predict worsening of symptoms (flares).
Biomarker studies performed during these flares
will identify factors in urine that increase with disease
activity and decrease during quiescent periods.
6. Groups of individuals with UCPPS exhibit a lower
overall pain threshold (i.e., hyperalgesia) compared
to asymptomatic controls. This left-shift in stimulus-
response function in the entire group of UCPPS
patients will be noted, both on quantitative sensory
testing, as well as within functional neuroimaging.
This finding in the entire group of UCPPS patients
will be shown to be driven by the subset of UCPPS
patients with the more “systemic” form of the disease
noted in Hypothesis 2 above.
7. Specific objective abnormalities (i.e., potential
biomarkers, including central pain processing and
modulation patterns (“brain signatures”) (Hypothesis
6) can be identified that are associated with specificrisk factors (Hypothesis 5), reflecting specific pain
processing and functional neuroimaging patterns
(Hypothesis 6).
8. Disease development in subsets of UCPPS patients’
results from an underlying pathogenic process, and
symptom exacerbations (flares) may be influenced
by changes in pathogen type or quantity.
The phenotyping approach developed in the MAPP Net-
work is the most comprehensive attempt to characterize
individuals with UCPPS to date, and one of the most com-
prehensive phenotyping projects undertaken for any form
of chronic pain. Examining not only urological factors, but
also non-urological factors consistent with the biopsycho-
social model of understanding chronic pain, broadens our
ability to explore underlying pathological mechanisms that
extend beyond the region of the pelvis. The observed vari-
ability across multiple domains within UCPPS suggests the
possibility of clinically relevant subgroups that may be used
to guide treatment in the future, or be used to understand
different causal factors of pain and urinary symptoms. In
addition, it is expected that future psychometric analyses
will help to translate this extensive phenotyping battery
into a set of assessment tools that can be applied in clinical
practice so as to guide treatment decisions.
Conclusions
The MAPP Research Network has successfully designed
and implemented a 48-week longitudinal, observational
study, focused on providing insights into underlying
pathophysiology and identifying clinically relevant phe-
notypes of UCPPS. Healthy control subjects, and posi-
tive controls exhibiting NUAS, were also phenotyped to
generate comparative data. Both baseline and longitu-
dinal data collection is complete for the Trans-MAPP
EP Study, which met or exceeded the original recruit-
ment targets. Protocol adherence proved excellent, espe-
cially participant data collection directly through novel
internet-based platforms. The biospecimen capture rate
reached nearly 100%, and the participant retention rate
for the final clinic visit at 48 weeks was 83% (349/420),
with remarkable adherence (83% missing no more than
3 monthly contacts). These statistics reveal critical suc-
cesses in the design and implementation of this complex,
multi-site clinical study. A comprehensive, multidimen-
sional battery of self-report measures is at the center of
the clinical phenotyping. This was assembled by network
investigators and incorporated into the Trans-MAPP
Network EP Study to correlate an array of domains, in-
cluding urologic symptoms, non-urologic pain, psycho-
social factors, risk factors, quality of life, among others,
in patients with UCPPS. Complementary data from inte-
grated multi-site biomarker studies, neuroimaging, ex-
perimental pain testing, and a number of additional
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form on pathophysiology and segregate clinically rele-
vant subgroups of individuals with UCPPS, for whom
diagnostics, treatments, and further studies of under-
lying pathological mechanisms can be targeted. These
complex data are currently being analyzed to provide a
systemic assessment of UCPPS patients and patient
groups.
It is expected that information obtained from these
studies will significantly aid in our understanding of the
pathophysiology and clinical characteristics of UCPPS,
inform future clinical efforts, and improve symptom man-
agement. Finally, the MAPP Research Network serves as a
new model for how large multi-disciplinary efforts may be
designed to investigate complex urologic, as well as non-
urologic, conditions.
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